Table 5 Comparison of cytogenetic abnormalities between MDS and AML patients

Genes mutation total events (mean, %)

2.02

1.78

0.147^#

 TET2

164 (50.5%)

72 (77.4%)

0.000001**

 ASXL1

62 (19.1%)

21 (22.6%)

0.4551

 CEBPA

56 (17.2%)

5 (5.4%)

0.0043**

 FLT3

53 (16.3%)

0 (0.0%)

0.000**

 DNMT3A

44 (13.5%)

5 (5.4%)

0.030962*

 NRAS

39 (12.0%)

7 (7.5%)

0.2242

 NPM1

36 (11.1%)

1 (1.1%)

0.002752

 RUNX1

25 (7.7%)

9 (9.7%)

0.536892

 IDH1

22 (6.8%)

0 (0.0%)

0.000**

 IDH2

22 (6.8%)

1 (1.1%)

0.000628**

 KIT

19 (5.8%)

0 (0.0%)

0.000**

 ETV6

9 (2.8%)

4 (4.3%)

0.0417*

 TP53

9 (2.8%)

5 (5.4%)

0.217879

 WT1

8 (2.5%)

0 (0.0%)

0.000**

 U2AF1

8 (2.5%)

18 (19.4%)

0.000**

 PHF6

8 (2.5%)

1 (1.1%)

0.417

 EZH2

7 (2.2%)

1 (1.1%)

0.503

 TTN

7 (2.2%)

0 (0.0%)

N/A

 SF3B1

7 (2.2%)

5 (5.4%)

0.101

 SRSF2

4 (1.2%)

5 (5.4%)

0.015

 JAK2

3 (0.9%)

2 (2.2%)

0.337

DNA methylation (frequency, %)

252 (77.5%)

72 (77.4%)

0.980646

RNA spliceosome (frequency, %)

20 (6.15%)

28 (30.1%)

0.000**

Chromatin remodelling (frequency, %)

69 (21.2%)

22 (23.7%)

0.617282

Transcriptional deregulation (frequency, %)

89 (27.4%)

14 (15.1%)

0.014963*

Activated signalling (frequency, %)

118 (36.3%)

10 (10.8%)

0.000002**